Avadel Pharmaceuticals (AVDL) has disclosed a new risk, in the Debt & Financing category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The Transaction Agreement in place for Avadel Pharmaceuticals imposes restrictions that limit the company’s ability to engage with third parties regarding alternative acquisition offers. These provisions may deter potential acquirers from proposing competitive bids, as they could be discouraged by the existing agreement’s terms. Consequently, this could result in a lower acquisition price being offered by potential competitors than might otherwise have been proposed. Such limitations could impact Avadel’s strategic options and shareholder value in the context of acquisition negotiations.
The average AVDL stock price target is $19.13, implying 0.90% upside potential.
To learn more about Avadel Pharmaceuticals’ risk factors, click here.